Fortress Biotech Inc reports results for the quarter ended December 31 - Earnings Summary

• Fortress Biotech Inc FBIO.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -75 cents. The mean expectation of two analysts for the quarter was for earnings of 11 cents per share. Wall Street expected results to range from -20 cents to 42 cents per share.

• Revenue rose 6.3% to $16.08 million from a year ago; analysts expected $26.17 million.

• Fortress Biotech Inc's reported EPS for the quarter was a loss of 1 cent​.

• The company reported a quarterly loss of $2.43 million.

• Fortress Biotech Inc shares had fallen by 11.5% this quarter and lost 32.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 131.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Fortress Biotech Inc is $10.75, about 77% above its last closing price of $2.47

This summary was machine generated from LSEG data April 2 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)